Evidence map›Paper›PMID 39995834›Full record

ArticleFrontiers in oncology2025

SiameseNet based on multiple instance learning for accurate identification of the histological grade of ICC tumors.

Zhizhan Fu, Fazhi Feng, Xingguang He, Tongtong Li, Xiansong Li, Jituome Ziluo, Zixing Huang, Jinlin Ye

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhizhan Fu *The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Fazhi Feng *Yangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, China.
Xingguang HeYangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, China.
Tongtong LiDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Xiansong LiDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Jituome ZiluoDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Zixing HuangDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Jinlin YeThe Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: After hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Timely and accurate identification of ICC histological grade is critical for guiding clinical diagnosis and treatment planning. Method: We proposed a dual-branch deep neural network (SiameseNet) based on multiple-instance learning and cross-attention mechanisms to address tumor heterogeneity in ICC histological grade prediction. The study included 424 ICC patients (381 in training, 43 in testing). The model integrated imaging data from two modalities through cross-attention, optimizing feature representation for grade classification. Results: In the testing cohort, the model achieved an accuracy of 86.0%, AUC of 86.2%, sensitivity of 84.6%, and specificity of 86.7%, demonstrating robust predictive performance. Conclusion: The proposed framework effectively mitigates performance degradation caused by tumor heterogeneity. Its high accuracy and generalizability suggest potential clinical utility in assisting histopathological assessment and personalized treatment planning for ICC patients.

Indexed as

cross-attention mechanismCT-based diagnosticshistological gradeintrahepatic cholangiocarcinomamultiple instance learning

Identifiers

PMID39995834
PMCPMC11847668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.